about
Peptides derived from HIV-1 gp120 co-receptor binding domain form amyloid fibrils and enhance HIV-1 infectionAnti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles.Potential strategies and biosafety protocols used for dual-use research on highly pathogenic influenza virusesReceptor-binding domain-based subunit vaccines against MERS-CoVAdvancements in the development of subunit influenza vaccinesCurrent advancements and potential strategies in the development of MERS-CoV vaccinesRational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations.Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptideStructure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitorTheaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitorsHIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected]Polyanionic candidate microbicides accelerate the formation of semen-derived amyloid fibrils to enhance HIV-1 infectionIdentification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strainsThe adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primatesEfficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1Visual and Motor Deficits in Grown-up Mice with Congenital Zika Virus InfectionVaccine design for severe acute respiratory syndrome coronavirus.Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.MERS-CoV spike protein: a key target for antivirals.Receptor-binding domain as a target for developing SARS vaccines.Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Receptor binding and transmission studies of H5N1 influenza virus in mammals.High genetic and antigenic similarity between a swine H3N2 influenza A virus and a prior human influenza vaccine virus: a possible immune pressure-driven cross-species transmission.E14-F55 combination in M2 protein: a putative molecular determinant responsible for swine-origin influenza A virus transmission in humans.An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virusAn H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virusReceptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.Genomic signature and protein sequence analysis of a novel influenza A (H7N9) virus that causes an outbreak in humans in China.Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development.Studying the nucleated mammalian cell membrane by single molecule approachesCombinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection.Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin.Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China.Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide StrategyPeptide and non-peptide HIV fusion inhibitors.A novel strategy for rapid construction of libraries of full-length antibodies highly expressed on mammalian cell surfaces.
P50
Q24339532-98B303FA-7B0F-4626-8352-2A5BC6A8EF2BQ24791794-1ABB2C1F-56D2-42D8-98A4-ECDFC7B9C0C2Q26825532-D5E71CA0-5D76-4C9A-88F6-156213B260B4Q26851979-81F93829-0462-43C5-A6CF-6FEF63B59EB2Q27010100-211525F7-6060-4606-AE84-1203031E0B49Q27012578-CC25DF27-2944-458C-9E29-D5E820B9D99AQ27315206-44855C59-B8C4-4A92-A33E-986CCE719103Q27644536-578BCC1F-F599-4207-B1CE-38406DCF94FAQ27689029-4CF0F534-518F-4C59-BB97-C614615D3145Q28244555-920A5A28-3BF5-4AA8-8181-DFF962B2D4A0Q28477409-8E6A95F1-74C1-4FB9-96F6-EB5329C0C220Q28485218-F5E523AF-3071-45D7-8B61-A4CF996B0286Q28489042-893BD82A-7FB1-418B-BB2F-999405017FDFQ28537991-E1EDDAC8-7AF4-43C4-A13A-347A74A63FC1Q28729899-89DF19CF-706A-4E70-B54B-33F0BDA25243Q28729936-B26111CC-E0E9-4280-8AC8-FE4426F0B7E1Q29571127-EB1CD7EC-56F8-4AE6-8F88-DF9A6B0E74DEQ30150777-FF1D1287-31DC-4962-98D0-7584384E57CDQ30218075-E36936A4-FEC2-40CF-A472-3FA3ADE9515BQ30240139-6D6B6A04-39A2-476B-A59F-A3249EE938EFQ30353170-71D0557A-3A5F-4CEE-A241-EE99B48FFE28Q30359335-8FEB1BE3-BD33-4B92-9BD1-AE51B3C91BD2Q30362113-17358ABB-626B-4D49-8001-AC1E7465D8F9Q30371303-110646A5-D9A2-4334-B98B-8796656834C3Q30375244-CB86A1C2-8B1A-470B-AAE9-970243D51209Q30377440-994C8629-9C8F-4C8D-BA62-5D8019E0DBA4Q30383802-D25D7021-5A86-46ED-AAD2-10D619D4FAA3Q30384563-06561FBD-B1A4-490A-88DF-CDFF61D52279Q30386561-00E919B3-2FF6-421A-8DB8-AA69AF8DB7C2Q30391315-C83F123B-5617-463A-A7A5-5F0FB0D0D42BQ30399700-AA2FF9D5-9A84-4D32-AFA1-C2D33F25C24AQ30429896-4FED6A3E-4D23-4926-AF12-621DDD5157D4Q30432706-1E7B66F0-79F0-44D8-8592-A4B30AAE1E12Q30438680-5C1A64BD-1FB3-458A-A530-B96A9C5CC904Q30499941-E2458EE5-0816-4FF9-A38B-46FB5568A4EFQ30535722-FCA94AAE-400B-48A8-9061-DC75CB05347CQ30537665-A6A3582B-1B48-4CFB-A1EA-AAC799147937Q30661709-BDF3227C-EEA9-41EF-A2BC-F05EC188FA50Q30831361-C4942A8E-D309-4594-9525-046FF037B0CBQ30987126-C07C0CD2-DB5A-4B07-963C-DF63067F7295
P50
description
researcher
@en
wetenschapper
@nl
name
Shibo Jiang
@en
Shibo Jiang
@nl
type
label
Shibo Jiang
@en
Shibo Jiang
@nl
altLabel
Jiang Shibo
@en
prefLabel
Shibo Jiang
@en
Shibo Jiang
@nl
P106
P21
P31
P496
0000-0003-1493-6523